Integra LifeSciences Holdings Corporation (IART): Price and Financial Metrics


Integra LifeSciences Holdings Corporation (IART)

Today's Latest Price: $55.62 USD

1.22 (2.24%)

Updated Nov 27 1:00pm

Add IART to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

IART Stock Summary

  • IART's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 259.28 -- higher than 87.91% of US-listed equities with positive expected earnings growth.
  • With a price/earnings ratio of 83.01, Integra Lifesciences Holdings Corp P/E ratio is greater than that of about 89.6% of stocks in our set with positive earnings.
  • In terms of volatility of its share price, IART is more volatile than merely 6.36% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Integra Lifesciences Holdings Corp are CW, MTSC, HRC, CMCO, and PNR.
  • Visit IART's SEC page to see the company's official filings. To visit the company's web site, go to www.integralife.com.

IART Stock Price Chart Interactive Chart >

Price chart for IART

IART Price/Volume Stats

Current price $55.62 52-week high $63.23
Prev. close $54.40 52-week low $34.21
Day low $54.44 Volume 74,400
Day high $55.62 Avg. volume 561,252
50-day MA $49.50 Dividend yield N/A
200-day MA $48.67 Market Cap 4.69B

Integra LifeSciences Holdings Corporation (IART) Company Bio


Integra LifeSciences develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neuro-surgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. The company was founded in 1989 and is based in Plainsboro, New Jersey.

IART Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$55.62$56.1 3%

We started the process of determining a valid price forecast for Integra Lifesciences Holdings Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Integra Lifesciences Holdings Corp ranked in the 48th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 3.5%. As for the metrics that stood out in our discounted cash flow analysis of Integra Lifesciences Holdings Corp, consider:

  • Its compound free cash flow growth rate, as measured over the past 5.67 years, is 0.3% -- higher than 67.87% of stocks in our DCF forecasting set.
  • Integra Lifesciences Holdings Corp's effective tax rate, as measured by taxes paid relative to net income, is at 14 -- greater than 54.67% of US stocks with positive free cash flow.
  • Relative to other stocks in its sector (Healthcare), Integra Lifesciences Holdings Corp has a reliance on debt greater than 70.06% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%1%
1%2%
2%3%
3%4%
4%5%
5%6%

Want more companies with a valuation profile/forecast similar to that of Integra Lifesciences Holdings Corp? See PAHC, FONR, LNTH, LCI, and INBP.


IART Latest News Stream


Event/Time News Detail
Loading, please wait...

IART Latest Social Stream


Loading social stream, please wait...

View Full IART Social Stream

Latest IART News From Around the Web

Below are the latest news stories about Integra Lifesciences Holdings Corp that investors may wish to consider to help them evaluate IART as an investment opportunity.

Integra Lifesciences to sell its extremity orthopedics business to Smith+Nephew for $240M

Integra LifeSciences (IART) to sell its Extremity Orthopedics business to Smith+Nephew (SNN) for $240M in cash.The transaction is expected to close at or around the end of 2020 and will not have a material impact on 2020 financial results. The Extremity Orthopedics business generated revenues of $90M in 2019 and ~$32.7M...

Seeking Alpha | September 29, 2020

" Intracranial Pressure Monitoring " Market 2020: Global Analysis, Industry Growth, Current Trends and Forecast till 2027 Medtronic Plc. (Ireland), RAUMEDIC Inc. (Germany), Integra LifeSciences Corporation

The Global Intracranial Pressure Monitoring Market Research Report offers an in-depth analysis of the Intracranial Pressure Monitoring industry and the economic scenario for business management that offers development and profitability for the key players in the market. The report on

OpenPR | September 28, 2020

Global Metacarpel Joint Implants Market Detailed Analysis Of Current And Future Industry Figures To 2027 | Major Giants –Integra LifeSciences Corporation, BioPro, Stryker, TEIJIN NAKASHIMA MEDICAL CO., LTD., Johnson & Johnson Medical Limited

DBMR has added a new report titled Global Metacarpel Joint Implants Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Global Metacarpel Joint

OpenPR | September 28, 2020

Integra LifeSciences Announces September 2020 Investor Conference Schedule

PRINCETON, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology…

GlobeNewswire | September 2, 2020

Global Digits Replacement Industry 2015-2030 and Impact of COVID-19 with Rank/Share Analysis of Integra LifeSciences, Stryker, Wright Medical Group and KLS Martin - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Digits Replacement (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering. This market model discusses in detail the impact of COVID-19 on Digits Replacement market for the year 2020 and beyond. Companies Mentioned Integra LifeSciences Corp. Stryker Corp. Wright Medical Group N.V. KLS Martin L.P. Although fusion is often still considered the treatment of choice the new ge

Business Wire | August 12, 2020

Read More 'IART' Stories Here

IART Price Returns

1-mo 26.12%
3-mo 16.38%
6-mo 4.69%
1-year -8.80%
3-year 14.40%
5-year 73.89%
YTD -4.56%
2019 29.22%
2018 -5.77%
2017 11.57%
2016 26.57%
2015 24.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.888 seconds.